What are Krystal Biotech, Inc.'s total assets?

Krystal Biotech, Inc. (KRYS) holds $1.4B in total assets, up 30.0% year over year.

How much debt does Krystal Biotech, Inc. have?

Krystal Biotech, Inc. carries $9.1M in total debt against $1.3B of shareholders' equity, a debt-to-equity ratio of 0.01.

How much cash does Krystal Biotech, Inc. have?

Krystal Biotech, Inc. holds $501.3M in cash and equivalents.

Can Krystal Biotech, Inc. cover its short-term obligations?

Its current ratio is 9.46 — current assets exceed current liabilities.

Where does Krystal Biotech, Inc.'s balance sheet data come from?

Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Krystal Biotech, Inc. KRYS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$496.3M+43.9%	$344.87M-3.8%	$358.33M+121%	$161.9M-52.6%
Short-term investments	$331.49M+31.2%	$252.65M+45.3%	$173.85M-20.0%	$217.27M+124%
Accounts receivable, net	$471.76M+15.1%	$410.03M+698%	$51.36M—	——
Inventories	$139.09M+104%	$68.31M+419%	$13.17M—	——
Raw materials	$15.94M+16.9%	$13.64M+332%	$3.15M—	——
Work in process	$15.22M+41.7%	$10.74M+235%	$3.2M—	——
Finished goods	$9.31M+338%	$2.13M+239%	$627K—	——
Prepaid expenses and other current assets	$14.91M+27.9%	$11.66M+73.8%	$6.71M+45.5%	$4.61M+10.5%
Income taxes receivable	$14.01M+766%	$1.62M—	——	——
Total current assets	$1.02B+38.1%	$742.05M+26.2%	$587.91M+53.2%	$383.78M-13.2%
Property and equipment, net	$150.78M-2.8%	$155.17M-3.7%	$161.2M-0.3%	$161.68M+43.9%
Accumulated depreciation	$31.28M+42.7%	$21.92M+70.9%	$12.83M+88.8%	$6.79M+61.2%
Operating lease right-of-use assets	9.7%-627,999,990%	628,000,000%-74,700,000%	702,700,000%-101,500,000%	804,200,000%+81,400,000%
Other non-current assets	$287K+24.2%	$231K-12.2%	$263K-18.8%	$324K+338%
Equity method investments	$128.07M-15.8%	$152.11M+146%	$61.95M+1,241%	$4.62M-92.8%
Total assets	$1.33B+26.3%	$1.06B+29.0%	$818.36M+46.5%	$558.45M-10.8%
Accounts payable	$3.24M-35.0%	$4.99M+20.6%	$4.13M+3.8%	$3.98M-52.6%
Accrued expenses	$3.58M+48.9%	$2.4M+28.1%	$1.88M+603%	$267K+207%
Operating lease liabilities, current	$1.77M+45.5%	$1.22M-17.4%	$1.47M-5.6%	$1.56M+50.0%
Income taxes payable	$10.92M+155%	$4.29M+87.8%	$2.28M+5,209%	$43K-48.2%
Total current liabilities	$102.94M+0.9%	$102M+208%	$33.09M+14.7%	$28.85M+12.1%
Operating lease liabilities, non-current	$7.57M+25.2%	$6.04M-8.7%	$6.62M-10.2%	$7.37M+5.6%
Operating Lease Liabilities (Total)	$9.34M+28.6%	$7.26M-10.3%	$8.09M-9.4%	$8.93M+11.3%
Other non-current liabilities	$3.72M+162%	$1.42M—	$0—	——
Total liabilities	$114.23M+4.4%	$109.46M+176%	$39.71M+9.6%	$36.22M+10.7%
Common stock	80M—	0—	0—	0—
Additional paid-in capital	$1.19B+5.9%	$1.13B+7.6%	$1.05B+30.4%	$803.72M+9.4%
Retained earnings	$24.16M+113%	-$180.67M+33.0%	-$269.83M+3.9%	-$280.76M-99.4%
Accumulated other comprehensive income (loss)	$1.14M+698%	-$190K-130%	$638K+188%	-$728K-347%
Total stockholders' equity	$1.22B+28.9%	$946.38M+21.5%	$778.64M+49.1%	$522.23M-12.0%
Total liabilities and stockholders' equity	$1.33B+26.3%	$1.06B+29.0%	$818.36M+46.5%	$558.45M-10.8%
Allowance for Doubtful Accounts	$68.12M+65.7%	$41.12M+478%	$7.11M—	——
Allowance for Doubtful Accounts Receivable (Current)	$68.12M+65.7%	$41.12M+478%	$7.11M—	——
Available For Sale Securities Debt Securities Current	$331.49M+31.2%	$252.65M+45.3%	$173.85M-20.0%	$217.27M+124%
Cash Cash Equivalents And Short Term Investments	——	——	——	——
Finished goods	$9.31M+338%	$2.13M+239%	$627K—	——
Deferred Tax Assets and Other Non-Current Assets	$287K+24.2%	$231K-12.2%	$263K-18.8%	$324K+338%
Net Investment in Lease	$7.24M+15.3%	$6.28M-10.6%	$7.03M-12.6%	$8.04M+11.3%
Deferred tax assets	$22.82M—	$0—	——	——
Investments	$128.07M-15.8%	$152.11M+146%	$61.95M+1,241%	$4.62M-92.8%
Operating lease right-of-use assets	$7.24M+15.3%	$6.28M-10.6%	$7.03M-12.6%	$8.04M+11.3%
Other non-current assets	$287K+24.2%	$231K-12.2%	$263K-18.8%	$324K+338%
Property, plant and equipment at cost	$182.06M+2.8%	$177.09M+1.8%	$174.03M+3.3%	$168.48M+44.5%
Operating Lease Right-of-Use Assets in Other Assets	$7.24M+15.3%	$6.28M-10.6%	$7.03M-12.6%	$8.04M+11.3%
Software and Technology Licenses, Net	$287K+24.2%	$231K-12.2%	$263K-18.8%	$324K+338%
Accrued liabilities and other current	$39.75M-32.6%	$58.99M+174%	$21.51M-7.7%	$23.31M+43.0%
Accrued rebates	$58.18M+58.1%	$36.8M+516%	$5.98M—	——
Other accrued liabilities	$3.58M+48.9%	$2.4M+28.1%	$1.88M+603%	$267K+207%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Professional Service Fees Payable	$5.94M+123%	$2.66M+46.9%	$1.81M-46.7%	$3.4M+68.9%
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Total debt	$9.34M+28.6%	$7.26M-10.3%	$8.09M-9.4%	$8.93M+11.3%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	29.2M+1.4%	28.8M+2.0%	28.2M+9.6%	25.8M+2.2%
Common Stock Shares Outstanding	$298.66M+91.0%	$156.4M+4.0%	$150.41M+132%	$64.88M+107%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	2M-0.9%	2M-21.4%	2.6M-27.2%	3.6M+75.3%
Unrealized Gains on Investments	$1.19M+59.7%	$745K-10.8%	$835K+366%	$179K+1,527%
Unrealized Losses on Investments (Before Tax)	$8K-98.0%	$406K+600%	$58K-93.1%	$835K+364%
Weighted Average Exercise Price of Outstanding Options	$99.45+20.3%	$82.69+24.6%	$66.39+8.0%	$61.50+7.9%
Cumulative Cost Basis	$182.06M+2.8%	$177.09M+1.8%	$174.03M+3.3%	$168.48M+44.5%
Accrued construction in progress	$2.19M-56.9%	$5.08M-2.0%	$5.18M-54.8%	$11.45M+19.2%
Accrued Expenses And Other Current Liabilities	$39.75M-32.6%	$58.99M+174%	$21.51M-7.7%	$23.31M+43.0%
Accrued inventory	$1.01M-17.4%	$1.22M+264%	$334K—	——
Accrued payroll and benefits	$11.46M+19.9%	$9.56M+8.9%	$8.78M+29.4%	$6.78M+135%
Accrued preclinical and clinical expenses	$4.67M+84.0%	$2.54M+103%	$1.25M-8.6%	$1.37M-14.8%
Professional service fees	$5.94M+123%	$2.66M+46.9%	$1.81M-46.7%	$3.4M+68.9%
Accounts Receivable, Allowance for Credit Loss	$68.12M+65.7%	$41.12M+478%	$7.11M—	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$8K-98.0%	$406K+600%	$58K-93.1%	$835K+364%
Gross Unrealized Gains	$1.19M+59.7%	$745K-10.8%	$835K+366%	$179K+1,527%
Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost	$954.68M+27.4%	$749.29M+26.3%	$593.36M+54.3%	$384.45M-23.5%
Cash Cash Equivalents And Debt Securities Available For Sale	$955.86M+27.5%	$749.63M+26.2%	$594.13M+54.8%	$383.79M-23.6%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$80M0.0%	$80M0.0%	$80M0.0%	$80M0.0%
Common stock, shares issued (in shares)	$29.19M+1.4%	$28.79M+2.0%	$28.24M+9.6%	$25.76M+2.2%
Common Stock, Shares, Outstanding	$29.19M+1.4%	$28.79M+2.0%	$28.24M+9.6%	$25.76M+2.2%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.1+2.1%	$0.10.0%	$0.1+1.1%	$0.09-1.1%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$2.03M-0.9%	$2.05M-21.4%	$2.61M-27.2%	$3.58M+75.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$99.45+20.3%	$82.69+24.6%	$66.39+8.0%	$61.5+7.9%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$298.66M+91.0%	$156.4M+4.0%	$150.41M+132%	$64.88M+107%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Krystal Biotech, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Krystal Biotech, Inc.'s total assets?: Krystal Biotech, Inc. (KRYS) holds $1.4B in total assets, up 30.0% year over year.
How much debt does Krystal Biotech, Inc. have?: Krystal Biotech, Inc. carries $9.1M in total debt against $1.3B of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Krystal Biotech, Inc. have?: Krystal Biotech, Inc. holds $501.3M in cash and equivalents.
Can Krystal Biotech, Inc. cover its short-term obligations?: Its current ratio is 9.46 — current assets exceed current liabilities.
Where does Krystal Biotech, Inc.'s balance sheet data come from?: Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.